Comparison of gadobenate dimeglumine with gadopentetate dimeglumine for magnetic resonance imaging of liver tumors

RATIONALE AND OBJECTIVES. To compare gadobenate dimeglumine (Gd-BOPTA) with gadopentetate dimeglumine (Gd-DTPA) for magnetic resonance imaging of the liver. METHODS. The contrast agent Gd-BOPTA or Gd-DTPA was administered at a dose of 0.1 mmol/kg to 257 patients suspected of having malignant liver tumors. Dynamic phase images, spin-echo images obtained within 10 minutes of inject ion, and delayed images obtained 40 to 120 minutes after injection were acq uired. All postcontrast images were compared with unenhanced TI-weighted an d T2-weighted images obtained immediately before injection. A full safety a ssessment was performed. RESULTS. The contrast efficacy for dynamic phase imaging was moderately or markedly improved in 90.9% (110/121) and 87.9% (109/124) of patients for Gd -BOPTA and Gd-DTPA, respectively. At 40 to 120 minutes after injection, the corresponding improvements were 21.7% (26/120) and 11.6% (14/121) for spin -echo sequences and 44.5% (53/119) and 19.0% (23/121) for breath-hold gradi ent-echo sequences, respectively. The differences at 40 to 120 minutes afte r injection were statistically significant (P < 0.02). Increased informatio n at 40 to 120 minutes after injection compared with information acquired w ithin 10 minutes of injection was available for 24.0% (29/121) of patients with Gd-BOPTA and for 14.5% (18/124) of patients with Gd-DTPA (P < 0.03). A dverse events were seen in 4.7% (6/128) and 1.6% (2/127) of patients receiv ing Gd-BOPTA and Gd-DTPA, respectively. The difference was not statisticall y significant. CONCLUSIONS. The efficacy of Gd-BOPTA is equivalent to that of Gd-DTPA for liver imaging during the dynamic phase and superior during the delayed (40- 120 minutes) phase of contrast enhancement. Both agents are safe for use in magnetic resonance imaging of the liver.